Each year since 2009, Eric Gelber, a CBRE Executive Vice President and ultra marathoner, has taken on increasingly challenging running feats to raise funds to find better treatments and eventually a cure for cancer, specifically multiple myeloma, a blood cancer which, at this time, is incurable. Since he began, Eric has raised over $500,000 and run thousands of miles for the Multiple Myeloma Research Foundation, (MMRF), to fund critical research that is extending the lives of cancer patients while getting closer to a cure.
It all began seven years ago when he decided to get off the couch and run his first marathon to raise funds for cancer research and honor his friend Anita Sorel, who was battling multiple myeloma. After that first marathon he was hooked. He started taking on longer distances and tougher challenges. His efforts have inspired others to change their lifestyles as they have trained to run along side him at various events, including 200 Miles Towards a Cure in 2014, where Eric ran for nearly 56 hours straight in New York City’s Central Park as he attempted to cover 200 miles (33 loops). Hundreds of everyday runners, patients and caregivers joined him as he sacrificed his own body while raising over $230,000 for the MMRF.
AUDACIOUS 2015 CHALLENGE
From July 28-30, 2015, Eric will take on what is dubbed “the world’s toughest footrace”, the Badwater 135 Ultramarathon., This exclusive invitation only race covers 135 miles, taking it’s participants from the lowest point in the United States at Badwater Basin, through Death Valley to the portal of Mt, Whitney at well over 8,000 feet. The race is held during the hottest time of year in the hottest place on earth with air temperatures consistently exceeding 120 degrees and the road temperature exceeds a shoe melting 180 degrees. His goal is to raise at least $250,000 for the MMRF, which will bring his all time fundraising to more than $750,000.
Multiple myeloma is, at this time, an incurable blood cancer. Although progress has been made in treating multiple myeloma, the five-year relative survival rate remains one of the lowest of all cancers. The MMRF has helped deliver seven new FDA approved drugs in less than 12 years, a track record unparalleled in oncology. The MMRF has helped reimagine the research system that is now speeding success across all forms of cancer.
The MMRF is the world’s leading private funder of myeloma research and one of the most highly regarded cancer foundations in the world. An outstanding 90% of the total MMRF budget goes directly towards cancer research and related programming, and they are consistently recognized in the top 1% of all charities reviewed by evaluators like Charity Navigator.